FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations. FLT3 in AML: Much more to learn about biology and optimal targeting

Francis J. Giles

doi:10.1016/j.leukres.2006.03.002

FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations. FLT3 in AML: Much more to learn about biology and optimal targeting

Francis J. Giles

Department of Cancer Biology

Research output: Contribution to a Journal (Peer & Non Peer) › Editorial

4 Citations (Scopus)

Abstract

Aberrant FLT3 function in leukemia blasts is associated with a poor prognosis. A number of FLT3 modulators are in development. FLT3 mutations may synergistize with other molecular abnormalities in myeloid transformation. Further insights into FLT3 biology are needed to optimally study the therapeutic role of FLT3 inhibitors.

Original language	English
Pages (from-to)	1469-1470
Number of pages	2
Journal	Leukemia Research
Volume	30
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2006.03.002
Publication status	Published - Dec 2006
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

FLT3
Inhibitiors
KRN383
PKC412

Access to Document

10.1016/j.leukres.2006.03.002

Cite this

@article{a32fe4b70a6844d1a504a12166ad23e2,

title = "FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations. FLT3 in AML: Much more to learn about biology and optimal targeting",

abstract = "Aberrant FLT3 function in leukemia blasts is associated with a poor prognosis. A number of FLT3 modulators are in development. FLT3 mutations may synergistize with other molecular abnormalities in myeloid transformation. Further insights into FLT3 biology are needed to optimally study the therapeutic role of FLT3 inhibitors.",

keywords = "FLT3, Inhibitiors, KRN383, PKC412",

author = "Giles, \{Francis J.\}",

year = "2006",

month = dec,

doi = "10.1016/j.leukres.2006.03.002",

language = "English",

volume = "30",

pages = "1469--1470",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "12",

}

TY - JOUR

T1 - FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations. FLT3 in AML

T2 - Much more to learn about biology and optimal targeting

AU - Giles, Francis J.

PY - 2006/12

Y1 - 2006/12

N2 - Aberrant FLT3 function in leukemia blasts is associated with a poor prognosis. A number of FLT3 modulators are in development. FLT3 mutations may synergistize with other molecular abnormalities in myeloid transformation. Further insights into FLT3 biology are needed to optimally study the therapeutic role of FLT3 inhibitors.

AB - Aberrant FLT3 function in leukemia blasts is associated with a poor prognosis. A number of FLT3 modulators are in development. FLT3 mutations may synergistize with other molecular abnormalities in myeloid transformation. Further insights into FLT3 biology are needed to optimally study the therapeutic role of FLT3 inhibitors.

KW - FLT3

KW - Inhibitiors

KW - KRN383

KW - PKC412

UR - https://www.scopus.com/pages/publications/33750026938

U2 - 10.1016/j.leukres.2006.03.002

DO - 10.1016/j.leukres.2006.03.002

M3 - Editorial

SN - 0145-2126

VL - 30

SP - 1469

EP - 1470

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations. FLT3 in AML: Much more to learn about biology and optimal targeting

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this